CU20190114A7 - COMBINATION TO SIMULTANEOUSLY INCREASE THE ANALGESIC EFFECTIVENESS OF MORPHINE AND REDUCE ITS PHYSICAL DEPENDENCE - Google Patents

COMBINATION TO SIMULTANEOUSLY INCREASE THE ANALGESIC EFFECTIVENESS OF MORPHINE AND REDUCE ITS PHYSICAL DEPENDENCE

Info

Publication number
CU20190114A7
CU20190114A7 CU2019000114A CU20190114A CU20190114A7 CU 20190114 A7 CU20190114 A7 CU 20190114A7 CU 2019000114 A CU2019000114 A CU 2019000114A CU 20190114 A CU20190114 A CU 20190114A CU 20190114 A7 CU20190114 A7 CU 20190114A7
Authority
CU
Cuba
Prior art keywords
morphine
physical dependence
combination
reduce
simultaneously increase
Prior art date
Application number
CU2019000114A
Other languages
Spanish (es)
Inventor
Fernández Pedro Gilberto Bárzaga
Suárez Bárbara Beatriz Garrido
Rodríguez Estael Ochoa
Yaquis Alejandro Saúl Padrón
Reyes Yamila Verdecia
Original Assignee
Centro De Investig Y Desarrollo De Medicamentos Cidem
Univ De La Habana Ministerio De Educacion Superior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro De Investig Y Desarrollo De Medicamentos Cidem, Univ De La Habana Ministerio De Educacion Superior filed Critical Centro De Investig Y Desarrollo De Medicamentos Cidem
Priority to CU2019000114A priority Critical patent/CU20190114A7/en
Priority to MX2022008002A priority patent/MX2022008002A/en
Priority to PCT/CU2020/050010 priority patent/WO2021139843A2/en
Priority to BR112022012692A priority patent/BR112022012692A2/en
Priority to CA3164100A priority patent/CA3164100A1/en
Priority to US17/788,815 priority patent/US20230054379A1/en
Publication of CU20190114A7 publication Critical patent/CU20190114A7/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

<p>La presente invención describe una combinación farmacéutica que incluye a una novedosa molécula con actividad neuroprotectora, para inhibir las neuroadaptaciones inducidas por la morfina (tolerancia e hiperalgesia). De esta forma incrementar su eficacia analgésica en condiciones normales y de daño neural, así como reducir los signos espontáneos de abstinencia asociados a la dependencia física.</p> <p> </p> <p> </p><p> The present invention describes a pharmaceutical combination that includes a novel molecule with neuroprotective activity, to inhibit the neuroadaptations induced by morphine (tolerance and hyperalgesia). In this way, it increases its analgesic efficacy under normal conditions and those of neural damage, as well as reducing the spontaneous signs of withdrawal associated with physical dependence. </p> <p> </p> <p> </p>

CU2019000114A 2019-12-26 2019-12-26 COMBINATION TO SIMULTANEOUSLY INCREASE THE ANALGESIC EFFECTIVENESS OF MORPHINE AND REDUCE ITS PHYSICAL DEPENDENCE CU20190114A7 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CU2019000114A CU20190114A7 (en) 2019-12-26 2019-12-26 COMBINATION TO SIMULTANEOUSLY INCREASE THE ANALGESIC EFFECTIVENESS OF MORPHINE AND REDUCE ITS PHYSICAL DEPENDENCE
MX2022008002A MX2022008002A (en) 2019-12-26 2020-12-18 Composition and method of treatment to simultaneously increase the analgesic efficacy of opioids and reduce their addictive power.
PCT/CU2020/050010 WO2021139843A2 (en) 2019-12-26 2020-12-18 Composition and method of treatment to simultaneously increase the analgesic efficacy of opioids and reduce their addictive power
BR112022012692A BR112022012692A2 (en) 2019-12-26 2020-12-18 COMPOSITION AND TREATMENT METHOD TO SIMULTANEOUSLY INCREASE THE ANALGESTIC EFFECTIVENESS OF OPIOIDS AND REDUCE THEIR ADDICTIVE POWER
CA3164100A CA3164100A1 (en) 2019-12-26 2020-12-18 Composition and method of treatment to simultaneously increase the analgesic efficacy of opioids and reduce their addictive power
US17/788,815 US20230054379A1 (en) 2019-12-26 2020-12-18 Composition and method of treatment to simultaneously increase the analgesic efficacy of opioids and reduce their addictive power

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU2019000114A CU20190114A7 (en) 2019-12-26 2019-12-26 COMBINATION TO SIMULTANEOUSLY INCREASE THE ANALGESIC EFFECTIVENESS OF MORPHINE AND REDUCE ITS PHYSICAL DEPENDENCE

Publications (1)

Publication Number Publication Date
CU20190114A7 true CU20190114A7 (en) 2021-08-06

Family

ID=76788894

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2019000114A CU20190114A7 (en) 2019-12-26 2019-12-26 COMBINATION TO SIMULTANEOUSLY INCREASE THE ANALGESIC EFFECTIVENESS OF MORPHINE AND REDUCE ITS PHYSICAL DEPENDENCE

Country Status (5)

Country Link
BR (1) BR112022012692A2 (en)
CA (1) CA3164100A1 (en)
CU (1) CU20190114A7 (en)
MX (1) MX2022008002A (en)
WO (1) WO2021139843A2 (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763626B2 (en) * 2004-06-18 2010-07-27 Trustees Of Dartmouth College Compositions and method for enhancing the therapeutic activity of opiods in treatment of pain
NZ565416A (en) * 2005-07-28 2011-03-31 Chiesi Farma Spa Therapeutic combination comprising a NMDA receptors blocker and a narcotic analgesic substance
CU20090172A6 (en) 2009-10-09 2011-10-05 Facultad De Quimica Universidad De La Habana TRICYCLIC AND TETRACYCLIC SYSTEMS WITH ACTIVITY ON THE CENTRAL AND VASCULAR NERVOUS SYSTEM
CU20160058A7 (en) 2016-05-04 2017-12-08 Centro De Investigación Y Desarrollo De Medicamentos (Cidem) Organizacion Superior De Desarrollo Emp DERIVED FROM BENZODIAZEPINA WITH ACTIVITY ON THE CENTRAL AND VASCULAR NERVOUS SYSTEM
CU24576B1 (en) 2016-05-04 2022-02-04 Centro De Investig Y Desarrollo De Medicamentos Cidem PHENOLIC COMPOUND AND COMBINATION THEREOF WITH A BENZODIAZEPINE FUSED TO 1,4-DIHYDROPYRIDINE FOR THE TREATMENT OF DISORDERS OF THE CENTRAL AND VASCULAR NERVOUS SYSTEM

Also Published As

Publication number Publication date
MX2022008002A (en) 2022-07-21
WO2021139843A2 (en) 2021-07-15
BR112022012692A2 (en) 2022-09-06
CA3164100A1 (en) 2021-07-15
WO2021139843A3 (en) 2022-01-13

Similar Documents

Publication Publication Date Title
CL2019000819A1 (en) Compounds and compositions to inhibit arginase activity. (divisional application 201801134)
CL2017000817A1 (en) Triazolopyrazinones as pde1 inhibitors
GT201600070A (en) CARBOXAMIDE DERIVATIVES AND ITS USE AS MEDICATIONS FOR THE TREATMENT OF HEPATITIS B
CO6640246A2 (en) Crystal form of the sglt2 benzylbenzene inhibitor
ECSP17072228A (en) Imidazopyrazinones as PDE1 inhibitors
BR112017011440A2 (en) an antimicrobial composition
BR112016025396A2 (en) heterocyclyl butanamide derivatives
BR112014019357A8 (en) TETRAHYDRO-QUINAZOLINONE DERIVATIVES AS TANC AND PARP INHIBITORS
CL2017000845A1 (en) Lysine Gingipain Inhibitors
ECSP23076906A (en) COMPOSITIONS AND METHODS FOR INHIBITING KETOHEXOKINASE (KHK)
PE20150721A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING GEMIGLIPTIN AND METFORMIN, AND METHOD FOR THEIR PREPARATION
ECSP16061208A (en) QUINAZOLIN-THF-AMINES AS PDE1 INHIBITORS
BR112016001928A2 (en) piperidine derivatives urea
CL2015002191A1 (en) Topical antifungal composition for the treatment of onychomycosis.
CR20140326A (en) TOPICAL PHARMACEUTICAL COMPOSITIONS THAT INCLUDE BEXATENO AND CORTICOSTEROIDS
CU20110146A7 (en) PHARMACEUTICAL COMPOSITIONS FROM C-FICOCIANINE DERIVATIVES AND COMBINATIONS WITH INTERFERONS OF TYPE I FOR THE TREATMENT OF ISCHEMICAL AND NEURODEGENERATIVE BRAIN DISEASES
CU20190114A7 (en) COMBINATION TO SIMULTANEOUSLY INCREASE THE ANALGESIC EFFECTIVENESS OF MORPHINE AND REDUCE ITS PHYSICAL DEPENDENCE
CR20160463A (en) QUINAZOLIN-THF-AMINAS HALOGENATED AS PDE1 INHIBITORS
CR20160322A (en) HEXAHYDROFUROPIRROLES AS PDE1 INHIBITORS
ES2721922T3 (en) Treatment or prevention of non-inflammatory neuronal damage due to brain trauma and stroke using menthol, linalool and / or icilin
CL2016002080A1 (en) Road widening structure, comprising a first portion resting on a support to support a first portion of the road, and a second cantilever portion secured to the first portion by a side wall to support a second portion of the road.
UY36222A (en) Tungsten salts (VI) for use in the treatment of infertility, to promote fertility and normal reproduction in a non-diabetic female mammal, as well as to improve the effectiveness of assisted reproduction techniques.
BR102014007923A8 (en) polymeric nanostructured system and its use
TH1701003631A (en) Quinazoline derivatives used to treat HIV
CL2017000162A1 (en) Tungsten salts (vi) for use in the treatment of infertility, to promote fertility and normal reproduction in a non-diabetic female mammal, as well as to improve the effectiveness of assisted reproduction techniques.